Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

吉利德科学（Gilead Sciences）与Kymera ...

吉利德科学（Gilead ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

临床试验显示， 该药对 HIV 感染的阻断率接近 100% ，远超现有每日口服药物 Truvada（需严格每日服用）。吉利德科学（Gilead Sciences）公司首席执行官丹尼尔・奥戴（Daniel O'Day）称，这是“HIV 防治史上的里程碑 ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...